Zhejiang Garden Biopharmaceutical Co.,Ltd.

Informe acción SZSE:300401

Capitalización de mercado: CN¥8.2b

Zhejiang Garden BiopharmaceuticalLtd Crecimiento futuro

Future controles de criterios 4/6

Zhejiang Garden BiopharmaceuticalLtd is forecast to grow earnings and revenue by 34.7% and 18.4% per annum respectively. EPS is expected to grow by 34.8% per annum. Return on equity is forecast to be 15.8% in 3 years.

Información clave

34.7%

Tasa de crecimiento de los beneficios

34.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals19.3%
Tasa de crecimiento de los ingresos18.4%
Rentabilidad financiera futura15.8%
Cobertura de analistas

Low

Última actualización03 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Profits May Not Reveal Underlying Issues

Oct 24
Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Profits May Not Reveal Underlying Issues

Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) Has A Somewhat Strained Balance Sheet

Sep 29
Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) Has A Somewhat Strained Balance Sheet

Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors

Sep 08
Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors

Why Investors Shouldn't Be Surprised By Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) 27% Share Price Surge

Jun 30
Why Investors Shouldn't Be Surprised By Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) 27% Share Price Surge

Is Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) A Risky Investment?

May 31
Is Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) A Risky Investment?

Subdued Growth No Barrier To Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401) With Shares Advancing 27%

May 06
Subdued Growth No Barrier To Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401) With Shares Advancing 27%

Why Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Shaky Earnings Are Just The Beginning Of Its Problems

Apr 22
Why Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Shaky Earnings Are Just The Beginning Of Its Problems

Previsiones de crecimiento de beneficios e ingresos

SZSE:300401 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/20261,854702N/A6541
12/31/20251,638553N/A5301
12/31/20241,446418N/A6571
9/30/20241,134285-88328N/A
6/30/20241,038217-140210N/A
3/31/20241,108232-133131N/A
12/31/20231,095192-85160N/A
9/30/20231,237179-134109N/A
6/30/20231,274204-83190N/A
3/31/20231,348284-45271N/A
1/1/20231,418384-3377N/A
9/30/20221,427466-62449N/A
6/30/20221,38546124677N/A
3/31/20221,329543-83660N/A
1/1/20221,117484-203512N/A
9/30/2021937409-77591N/A
6/30/2021847420-223385N/A
3/31/2021699293-139455N/A
12/31/2020659263-166427N/A
9/30/2020630261-341311N/A
6/30/2020645277-218366N/A
3/31/2020617276-264275N/A
12/31/2019718344-80367N/A
9/30/2019763392125410N/A
6/30/201975838479322N/A
3/31/201966131591318N/A
1/1/201966030735253N/A
9/30/201858525221193N/A
6/30/2018508208N/A224N/A
3/31/2018569232N/A229N/A
1/1/2018420130N/A148N/A
9/30/2017416120N/A117N/A
6/30/2017403103N/A98N/A
3/31/201735560N/A75N/A
12/31/201632944N/A49N/A
9/30/201627229N/A65N/A
6/30/201623917N/A26N/A
3/31/201617810N/A22N/A
12/31/201515112N/A43N/A
9/30/201515222N/A42N/A
6/30/201515833N/A12N/A
3/31/201516338N/A-16N/A
12/31/201415937N/A-12N/A
9/30/201415840N/A39N/A
12/31/201318436N/A114N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: 300401's forecast earnings growth (34.7% per year) is above the savings rate (2.9%).

Beneficios vs. Mercado: 300401's earnings (34.7% per year) are forecast to grow faster than the CN market (25.8% per year).

Beneficios de alto crecimiento: 300401's earnings are expected to grow significantly over the next 3 years.

Ingresos vs. Mercado: 300401's revenue (18.4% per year) is forecast to grow faster than the CN market (14% per year).

Ingresos de alto crecimiento: 300401's revenue (18.4% per year) is forecast to grow slower than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: 300401's Return on Equity is forecast to be low in 3 years time (15.8%).

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y